CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Merrimack Pharmaceuticals today announced that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. William Sullivan, Vice President of Finance, will provide a company overview at 11:30am, EDT, Friday, September 17, 2010 at the Four Seasons Hotel in Boston, Massachusetts.
(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20100913/NE63515LOGO )
About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack has three oncology candidates in clinical development: MM-121, partnered with sanofi-aventis, in Phase 2 clinical testing, MM-111 in Phase 1/2 clinical testing, MM-398, partnered with PharmaEngine, Inc., in Phase 2 clinical testing and multiple pre-clinical development and research stage programs in the pipeline. MM-121, MM-111, and MM-398 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.
Contacts | |
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli@merrimackpharma.com, http://www.merrimackpharma.com | |
Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy@raymondstevenson.com | |
SOURCE Merrimack Pharmaceuticals, Inc.
